Skip to content

Effect of Synapse Medicine Decision Support on Inpatient Pharmacist Efficacy and Efficiency

Effect of Synapse Medicine Decision Support on Inpatient Pharmacist Efficacy and Efficiency: a Hybrid Type 2 Implementation Study

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05459155
Enrollment
1485
Registered
2022-07-14
Start date
2023-05-31
Completion date
2026-06-02
Last updated
2026-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Diseases, Heart Diseases, Infections, Kidney Diseases, Liver Diseases, Lung Diseases

Keywords

Hospitalized Patients

Brief summary

Adverse drug events (ADE) are common and dangerous in the hospital and following discharge to the ambulatory setting. One cause of ADEs in both settings is medication regimen inappropriateness, including polypharmacy, drug-drug interactions, and medications that are inappropriate or inappropriately dosed given patients' age, renal, and hepatic function. Hospitalization provides a good opportunity to investigate medication appropriateness given new or worsening conditions and available expertise. Inpatient pharmacists are medication experts and often round with medical teams, but they may not always have all the information available at their fingertips to make optimal recommendations regarding medication appropriateness for each patient. Clinical decision support to pharmacists at the point of care has potential to improve the speed, quantity, and quality of medication recommendations to inpatient teams; any subsequent improvements to medication regimen appropriateness have the potential to reduce ADEs in the hospital and after discharge. Specific Aims and Objectives Aim 1: Implement real-time decision support regarding medication regimen appropriateness among pharmacists who round with inpatient medical teams. Aim 2: Determine the effects of this intervention on the number of medication regimen recommendations and time spent per recommendation Aim 3: Evaluate the use and usability of the decision support tool and develop strategies to mitigate barriers and promote facilitators of implementation using mixed methods implementation science approaches.

Detailed description

This will be a prospective pre-post mixed methods hybrid type 2 effectiveness-implementation study. The study will take place at BWH and at Vanderbilt University Medical Center (VUMC). The direct subjects will be the inpatient pharmacists (4 at each site) who round with general medicine teams. Patients will be indirect subjects as pharmacists provide medication recommendations regarding these patients to the clinicians on each team with or without the Synapse software. We estimate this number of patients to be 3 new admitted patients per day per team x 56 days x 8 teams = 1344 patients (672 at MGB sites). Patients can be any patients admitted to these general medicine service teams at BWH and VUMC. The pharmacists are trained hospital pharmacists who round with general medicine service teams and approve inpatient medication orders. There are no local site restrictions. VUMC will cede IRB approval to the MGB IRB.

Interventions

OTHERSynapse medicine platform

Intervention is the Synapse medicine platform for inpatient pharmacists. This software analyzes drug-related risks based on each patient's clinical characteristics

Sponsors

Brigham and Women's Hospital
Lead SponsorOTHER
Synapse Medicine
CollaboratorUNKNOWN
Vanderbilt University Medical Center
CollaboratorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

Prospective pre-post mixed methods hybrid type 2 effectiveness-implementation study

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* any patient that the inpatient pharmacists care for on the inpatient medical team they round with

Exclusion criteria

* N/A

Design outcomes

Primary

MeasureTime frameDescription
Change in the number of medication recommendations made per patientpre- and post-intervention periods: 4 weeks each per pharmacistChange from pre- to post-intervention in the number of recommendations regarding medication changes made by pharmacists per patient

Secondary

MeasureTime frameDescription
Change in the time spent per recommendation per patientpre- and post-intervention periods: 4 weeks each per pharmacistChange from pre- to post-intervention in time spent per patient evaluating regimen appropriateness divided by the number of recommendations for that patient

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 4, 2026